| MeSH term | MeSH ID | Detail |
|---|---|---|
| Insulin Resistance | D007333 | 99 associated lipids |
| Weight Gain | D015430 | 101 associated lipids |
| Glioma | D005910 | 112 associated lipids |
| Hypertension | D006973 | 115 associated lipids |
| Inflammation | D007249 | 119 associated lipids |
| Cell Transformation, Neoplastic | D002471 | 126 associated lipids |
| Hemolysis | D006461 | 131 associated lipids |
| Carcinoma, Hepatocellular | D006528 | 140 associated lipids |
| Edema | D004487 | 152 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Dumont FJ et al. | The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. | 1990 | J. Immunol. | pmid:1689353 |
| Brown Z and Neild GH | FK-506 and haemolytic uraemic syndrome. | 1990 | Lancet | pmid:1689442 |
| Thomas J et al. | The immunosuppressive action of FK506. In vitro induction of allogeneic unresponsiveness in human CTL precursors. | 1990 | Transplantation | pmid:1689518 |
| Vathsala A et al. | Analysis of the interactions of immunosuppressive drugs with cyclosporine in inhibiting DNA proliferation. | 1990 | Transplantation | pmid:1689520 |
| Yamamoto K et al. | Experimental treatment of autoimmune MRL-lpr/lpr mice with immunosuppressive compound FK506. | 1990 | Immunology | pmid:1689694 |
| Thomson AW | Interspecies comparison of the immunosuppressive efficacy and safety of FK 506. | 1990 | Transplant. Proc. | pmid:1689883 |
| Zeevi A et al. | Functional differentiation of human cytotoxic T lymphocytes in the presence of FK 506 and CyA. | 1990 | Transplant. Proc. | pmid:1689884 |
| Ohara K et al. | Toxicologic evaluation of FK 506. | 1990 | Transplant. Proc. | pmid:1689910 |
| Nalesnik MA et al. | The effect of FK 506 and CyA on the Lewis rat renal ischemia model. | 1990 | Transplant. Proc. | pmid:1689911 |
| Francavilla A et al. | FK 506 as a growth control factor. | 1990 | Transplant. Proc. | pmid:1689912 |
| Mazzaferro V et al. | Studies of the hepatotrophic qualities of FK 506 and CyA. | 1990 | Transplant. Proc. | pmid:1689913 |
| Kay JE et al. | The mechanism of action of FK 506. | 1990 | Transplant. Proc. | pmid:1689914 |
| Suzuki N et al. | Effects of a novel immunosuppressive agent, FK506, on human B cell activation. | 1990 | Clin. Exp. Immunol. | pmid:1690097 |
| McCauley J et al. | FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. | 1990 | Lancet | pmid:1690326 |
| Hoffman AL et al. | The use of FK-506 for small intestine allotransplantation. Inhibition of acute rejection and prevention of fatal graft-versus-host disease. | 1990 | Transplantation | pmid:1690469 |
| Woo J et al. | Flow cytometric analysis of lymphocyte populations and activation antigen expression in blood and lymphoid tissues of FK 506-treated rats. | 1990 | Transplant. Proc. | pmid:1697112 |
| Woo J et al. | Effects of FK 506 and low concentration cyclosporine on human lymphocyte activation antigen expression: a flow cytometric analysis. | 1990 | Transplant. Proc. | pmid:1697113 |
| Propper DJ et al. | Low-dose FK 506 inhibits sensitisation after blood transfusions. | 1990 | Transplant. Proc. | pmid:1697114 |
| Tiebosch A et al. | Side effects of FK 506 in cynomolgus monkeys: a histopathologic study. | 1990 | Transplant. Proc. | pmid:1697115 |
| Dammeijer PF et al. | Combined effect of low-dose FK 506 and cyclosporine A on skin graft survival. | 1990 | Transplant. Proc. | pmid:1697116 |
| Imai K et al. | Pancreaticoduodenal allotransplantation with the use of FK 506, cyclosporine, and triple-regimen immunosuppression. | 1990 | Transplant. Proc. | pmid:1697117 |
| Iga C et al. | Prolonged survival of small intestinal allograft in the rat with cyclosporine A, FK 506, and 15-deoxyspergualin. | 1990 | Transplant. Proc. | pmid:1697118 |
| Deguchi K et al. | [Effects of novel immunosuppressant FK 506 in acute experimental allergic encephalomyelitis]. | 1990 | No To Shinkei | pmid:1697182 |
| Tsuji RF et al. | Selective immunosuppression of prodigiosin 25-C and FK506 in the murine immune system. | 1990 | J. Antibiot. | pmid:1701765 |
| Granelli-Piperno A et al. | The effect of immunosuppressive agents on the induction of nuclear factors that bind to sites on the interleukin 2 promoter. | 1990 | J. Exp. Med. | pmid:1701825 |
| Lee KK et al. | Comparison of short-term immunosuppressive therapy with cyclosporine and FK 506 in small-bowel transplantation. | 1990 | Transplant. Proc. | pmid:1702239 |
| Takai K et al. | Effects of FK506 on rat thymus: time-course analysis by immunoperoxidase technique and flow cytofluorometry. | 1990 | Clin. Exp. Immunol. | pmid:1702372 |
| Okubo Y et al. | FK506, a novel immunosuppressive agent, induces antigen-specific immunotolerance in active Heymann's nephritis and in the autologous phase of Masugi nephritis. | 1990 | Clin. Exp. Immunol. | pmid:1702373 |
| Arita C et al. | Inhibition by FK506 of established lesions of collagen-induced arthritis in rats. | 1990 | Clin. Exp. Immunol. | pmid:1702374 |
| Woo J et al. | Influence of FK506 and cyclosporin A on alloantibody production and lymphocyte activation following blood transfusion. | 1990 | Clin. Exp. Immunol. | pmid:1702375 |
| Wasik M et al. | Effect of FK-506 and cyclosporine on human T and B lymphoproliferative responses. | 1990 Jul-Aug | Immunopharmacology | pmid:1699911 |
| MacLeod AM and Thomson AW | [FK-506. A new immunosuppressive drug]. | 1990 Jul-Sep | Medicina (Firenze) | pmid:1706817 |
| Naouri A and Tissot E | [Indications for liver transplantation in adults]. | 1990 Jun-Jul | J Chir (Paris) | pmid:1698800 |
| Gailliot FP et al. | Fluidized bed adsorption for whole broth extraction. | 1990 Sep-Oct | Biotechnol. Prog. | pmid:1366874 |
| FK-506 shows similar graft survival rate to cyclosporine but fewer side effects: Pitt transplant team. | 1991 | Nephrol News Issues | pmid:1720511 | |
| Ito T et al. | The mechanism of tolerance induced by a perioperative injection of bone marrow cells and a brief course of FK 506. | 1991 | Transplant. Proc. | pmid:1703716 |
| The discovery of FK-506 and U.S. development. | 1991 | Nephrol News Issues | pmid:1720512 | |
| Zheng B et al. | Effects of the new and highly active immunosuppressant, rapamycin, on lymphoid tissues and cells in vivo. | 1991 | Transplant. Proc. | pmid:1703717 |
| Habucky K et al. | The pharmacodynamics of pentobarbital following FK 506 therapy. | 1991 | Transplant. Proc. | pmid:1721282 |
| McCarthy SA et al. | Effects of FK 506 and cyclosporine on T-cell tolerance: inhibition of a "protective" mechanism that regulates activation-induced apoptosis in developing thymocytes. | 1991 | Transplant. Proc. | pmid:1721314 |
| Nakamura K et al. | The lymphocytotoxic crossmatch in liver transplantation: a clinicopathologic analysis. | 1991 | Transplant. Proc. | pmid:1721346 |
| Jain AB et al. | Correlation of rejection episodes with FK 506 dosage, FK 506 level, and steroids following primary orthotopic liver transplant. | 1991 | Transplant. Proc. | pmid:1721347 |
| Perico N et al. | FK 506 does not affect the glomerular filtration rate and renal plasma flow in the rat. | 1991 | Transplant. Proc. | pmid:1721378 |
| Mieles L et al. | Glycemia and insulin need following FK 506 rescue therapy in liver transplant recipients. | 1991 | Transplant. Proc. | pmid:1703362 |
| Tai J et al. | In vivo and in vitro effect of FK 506 on rat Leydig cell function. | 1991 | Transplant. Proc. | pmid:1721409 |
| Ricordi C et al. | Human islet allotransplantation under FK 506. | 1991 | Transplant. Proc. | pmid:1721410 |
| Katayama Y et al. | Immunosuppressive effects of FK 506 in rat lung transplantation. | 1991 | Transplant. Proc. | pmid:1721441 |
| Albers MW et al. | Relationship of FKBP to PKCI-2. | 1991 | Nature | pmid:1710782 |
| Chen MF et al. | The influence of FK-506 on the thymus and spleen in normal C3H/He mice: flow cytometric analysis of lymphocyte subpopulations. | 1991 | Immunol. Lett. | pmid:1722778 |
| Lautenschlager I et al. | Efficiency of FK 506 and CyA to prevent acute cellular rejection of pig liver allografts. | 1991 | Transplant. Proc. | pmid:1714650 |